Novartis’s Cosentyx Secures Qualified Win In Hidradenitis Suppurativa
Moving Towards Ten Approvals For Blockbuster
The Swiss major’s Cosentyx has succeeded in two trials for the debilitating skin condition but there are concerns that the data may not be sufficient to shift AbbVie’s Humira off the top spot for treatment.
